Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:26:03 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:SYRE - SPYRE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SYRE - Q0.129.92·31.192.030.66+1.966.81,127.133,9464,42828.41  30.70  28.4147.97  10.4216:43:4308:0015 min RT 2¢

Recent Trades - Last 10 of 4428
Time ETExPriceChangeVolume
16:43:43Q31.192.4915
16:13:06Q30.011.3130
16:08:19Q30.661.966,720
16:03:16Q30.661.962,847
16:01:34Q30.661.96128
16:01:32Q30.661.96207
16:01:12Q30.661.96263
16:00:06Q30.661.96522,593
16:00:04Q30.661.963,587
16:00:04Q30.661.964

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-14 08:00U:SYRENews ReleaseSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
2024-10-04 17:00U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-10-01 08:00U:SYRENews ReleaseSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
2024-09-10 16:47U:SYRENews ReleaseSpyre Therapeutics to Participate in Upcoming Investor Conference
2024-08-07 16:05U:SYRENews ReleaseSpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-07-18 08:00U:SYRENews ReleaseNewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
2024-06-18 07:30U:SYRENews ReleaseSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-alpha4beta7 Antibody, for the Treatment of Inflammatory Bowel Disease
2024-06-03 17:23U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-05-29 08:30U:SYRENews ReleaseSpyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
2024-05-15 07:30U:SYRENews ReleaseSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
2024-05-09 16:02U:SYRENews ReleaseSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-03 17:00U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-04-01 17:00U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-03-18 08:00U:SYRENews ReleaseSpyre Therapeutics Announces $180 Million Private Placement
2024-03-01 17:25U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-02-29 16:05U:SYRENews ReleaseSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-26 07:30U:SYRENews ReleaseSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
2024-02-08 07:30U:SYRENews ReleaseSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
2024-02-05 07:30U:SYRENews ReleaseSpyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
2024-02-02 17:30U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards